Financial Performance - Improved loss from operations to $2.4 million for Q3 2024, a 31% improvement from a loss of $3.6 million in Q3 2023 [5] - Net product sales decreased by 12% to $4.5 million in Q3 2024, down from $5.1 million in the prior year period [4] - Net loss attributable to common stockholders was $2.4 million, or a loss of $0.02 per share, for Q3 2024 [6] Operating Expenses - Total operating expenses were $6.9 million, a decrease of 20% compared to the prior year period [4] - Selling and marketing costs decreased by 20% to $2.4 million compared to the prior year quarter [8] - Research and development costs decreased by 46% to $0.3 million compared to the prior year quarter [8] Investments and Acquisitions - Aditxt, Inc. invested $5.0 million in Evofem since May 2024, including $1.3 million in Q3 2024 [2] - Acquired global rights to SOLOSEC, a single-dose oral antibiotic FDA-approved for bacterial vaginosis and trichomoniasis [2] - Licensed Phexxi commercial rights in the Middle East, with regulatory submission to the UAE Ministry of Health expected by year-end 2024 [2] Cash Position - At September 30, 2024, the company had $0.7 million of restricted cash, up from $0.6 million at December 31, 2023 [9]
EVOFEM BIOSCIENC(EVFM) - 2024 Q3 - Quarterly Results